Comments
FDC on Tuesday announced the launch of Favipiravir-PiFLU and Favenza, which will be used to treat mild to moderate cases of Covid-19 in India. With the third-largest number of cases globally at close to three million and a growing daily increase rate, the economy and populace have been struck by the pandemic over the past two quarters.
Earlier this year, the Drug Controller General of India (DCGI) approved the use of Favipiravir, an off-patent, oral anti-viral drug that has been shown to quicken clinical recovery in Covid-19 patients with mild to moderate symptoms. It is a broad-spectrum anti-viral agent, and selectively inhibits RNA polymerase of influenza and Sarcov-2 virus and prevents viral replication.
On Wednesday’s noon trade, the shares gained as much as 6.4 per cent to ₹337.8.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.